CenterPoint Energy (CNP) PT Raised to $43 at Wolfe Research
Get Alerts CNP Hot Sheet
Rating Summary:
14 Buy, 15 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 18 | New: 50
Join SI Premium – FREE
Wolfe Research analyst Steve Fleishman raised the price target on CenterPoint Energy (NYSE: CNP) to $43.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "We are Outperform rated on CNP. We like CNP’s core utility story with projected rate base growth of ~11% through 2030, which places it amongst the highest within the entire sector. Robust rate base opportunities are underpinned by solid customer growth in key service territories – Houston Electric expects ~2% customer growth annually for the foreseeable future and CNP’s gas LDCs experience about 1% customer growth annually. This growth profile is aided by targeted annual 1-2% O&M reductions, which will help keep the impact to customer bills manageable; securitization charge roll-offs also provide headroom on customer bills (~4% of the current average residential bill rolled off in Oct. 2024). Since Hurricane Beryl, CNP has made considerable progress in correcting its mis-steps: accelerating resiliency initiatives and settling a revised System Resiliency Plan (SRP), proposing a constructive mobile gen. solution, receiving approval for an uncontested settlement in CEHE's rate case with a boost to both ROE/equity ratio, and advancing its capital tracker filings. CNP also has L-T capex/EPS upside potential from incremental transmission investment in Houston driven by TX's strong organic growth, higher SRP spend beyond 2028, modernizing substations to support Houston downtown's revitalization, localized transmission/high-pressure distribution at TX Gas, and transmission/data centers at IN Electric. Thus, we believe that CNP deserves to trade at a ~20-25% premium to our targeted group average of ~17.0x in 2027."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts LB Pharmaceuticals Inc (LBRX) at Outperform
- Nebius Group (NBIS) PT Raised to $410 at Northland
- Humana (HUM) PT Raised to $410 at BofA Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share